8-K
Entry into a Material Definitive Agreement
Show detailsHide details
1.01 Entry into a Material Definitive Agreement · 1.03 Bankruptcy or Receivership
BTAI
Bioxcel Therapeutics, Inc.
A biopharmaceutical company that turns already-approved drugs into new treatments, using AI to "re-innovate" existing medicines. Its lead product, IGALMI, is a small dissolvable film placed under the tongue that calms sudden agitation in people with schizophrenia or bipolar disorder. Founded in 2017 and based in New Haven, Connecticut, the company skipped traditional venture funding and went straight to the public markets the following year — with a name that blends "bio" with a nod to accelerating drug development.
CUSIP: 09075P204HealthcareUS1 holder